| Regenerative Medicine Press Releases + Feed Topics Locations Industries Dates
By Blue Horizon International Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons in San Diego, CA from March 14-18, 2017 at the San...
| By Stemedica International Peer-reviewed Research Published in Nature's "Scientific Reports"
| By Blue Horizon International Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending the 47th Annual World Economic Forum (WEF) in Davos from January 17-20, 2017.
| By Stemedica International Alexei Lukashev, PhD, General Manager, Awarded First Place in Russian Speaking Entrepreneur of the Year Competition
| By Stemedica International The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
| By ReGen Medical Dr. Steven Victor, CEO of ReGen Medical P.C., New York, stated "I am honored and pleased to now be certified by the Board of Regenerative Medicine after practicing this new and exciting specialty of medicine for the past 10 years." The American Academy...
| By Lipogems Lipogems, a global leader in regenerative medicine, has been named a recipient of Orthopedics This Week's "Best New Sports Medicine Technology of 2016" Award.
|  | By The Transplantation Society 26th International Congress of The Transplantation Society - August 18-23
|  | By The CHARMED Foundation The CHARMED Foundation is the first of its kind to support regenerative medicine research specific to pediatric illnesses and sports medicine
|  | By Blue Horizon International Brian Mehling, M.D., board-certified orthopedic surgeon and CMO of Blue Horizon International, presents data from “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Stemedica International, SA Stemedica International, a subsidiary of Stemedica Cell Technologies, Inc.
| By AmnioChor Inc. AmnioChor Inc., an early stage biotech startup based on perinatal stem cell technology, is very pleased to announce that the Musculoskeletal Transplant Foundation of Edison NJ has agreed to invest in their seed round of development of the proprietary...
|  | By Blue Horizon International Dr. Mehling, a board-certified orthopedic surgeon and CMO of Blue Horizon International (BHI), will present “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Medical Tourism Association® Panel Discussion Examines "Innovations in Stem Cell Treatments and Regenerative Medicine," Sept. 20, 2014, in Washington, D.C.
| By Blue Horizon Charitable Foundation Karina C. Tyler is a busy executive assistant who lives and works in New York City. Originally from Brazil, she juggles her limited time between her career, her family, and her passion for sports and travel.
| By Carmell Therapeutics Corp. Carmell Therapeutics, a company that is developing novel products manufactured from blood plasma, which naturally accelerate the healing of injured tissues, is pleased to announce that it has been awarded a Phase I Small Business Innovation Research...
|  | By Xcelthera Inc Xcelthera Inc Secures First U.S. Patent for Large-Scale Production of High Quality Human Embryonic Stem Cells and their Neuronal and Heart Muscle Cell Therapy Products
| By Blue Horizon International Researchers study the benefits of regenerative medicine in spinal cord injury
| By Blue Horizon International Robert, a 67-year-old physician, who lives in California is an avid outdoorsman who enjoys leading an active lifestyle.
|  | By South Florida Bone Marrow Stem Cell Trans. Inst. On March 8 2014, Dr. Dipnarine Maharaj delivered the keynote address for the Annie Appleseed conference in West Palm Beach, FL. The conference featured leading speakers from North America on common and alternative modalities for cancer treatment.
|
All Press Releases
By Coherent Market Insights Regenerative Medicine Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024
| By Blue Horizon International Brian Mehling, M.D. and Pavel Yufit, M.D., orthopedic surgeons with practices in New York and New Jersey, are scheduled to attend the 2017 Annual Meeting of the American Academy of Orthopaedic Surgeons in San Diego, CA from March 14-18, 2017 at the San...
| By Stemedica International Peer-reviewed Research Published in Nature's "Scientific Reports"
| By Blue Horizon International Brian Mehling, M.D., world-renowned stem cell researcher, board-certified orthopedic trauma surgeon, and founder of Blue Horizon International (BHI), will be attending the 47th Annual World Economic Forum (WEF) in Davos from January 17-20, 2017.
| By Stemedica International Alexei Lukashev, PhD, General Manager, Awarded First Place in Russian Speaking Entrepreneur of the Year Competition
| By Stemedica International The Only Alzheimer's Disease Clinical Trial Using Stemedica's Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) Continues Recruitment at UCI
| By ReGen Medical Dr. Steven Victor, CEO of ReGen Medical P.C., New York, stated "I am honored and pleased to now be certified by the Board of Regenerative Medicine after practicing this new and exciting specialty of medicine for the past 10 years." The American Academy...
| By Lipogems Lipogems, a global leader in regenerative medicine, has been named a recipient of Orthopedics This Week's "Best New Sports Medicine Technology of 2016" Award.
| | By The Transplantation Society 26th International Congress of The Transplantation Society - August 18-23
| By charleston sports medicine Dr. Bright McConnell focuses on regenerative medicine and takes a minimally invasive approach to treatment of injuries at Charleston Sports Medicine. One treatment, Subchondroplasty, may prevent some from undergoing total knee replacement.
| By Visiongain A new report by visiongain predicts that the Translational Regenerative Medicine market will reach $12.1bn in 2020.
| | By The CHARMED Foundation The CHARMED Foundation is the first of its kind to support regenerative medicine research specific to pediatric illnesses and sports medicine
| By Charleston Sports Medicine At Charleston Sports Medicine, Bright McConnell, III, MD combines traditional orthopedics with cutting-edge techniques in regenerative medicine. www.charlestonsportsmed.com.
| | By Blue Horizon International Brian Mehling, M.D., board-certified orthopedic surgeon and CMO of Blue Horizon International, presents data from “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Stemedica International, SA Stemedica International, a subsidiary of Stemedica Cell Technologies, Inc.
| By Shibuya Kogyo Co Ltd Patent and technical know-how licensing agreement between Yamaguchi University and Shibuya Kogyo, Co. Ltd. for advanced regenerative medicine treatment for liver disease.
| By Shibuya Kogyo Co Ltd Shibuya Announces Business Expansion in Regenerative Medicine Market
| By AmnioChor Inc. AmnioChor Inc., an early stage biotech startup based on perinatal stem cell technology, is very pleased to announce that the Musculoskeletal Transplant Foundation of Edison NJ has agreed to invest in their seed round of development of the proprietary...
| By Mary Ann Liebert Inc., publishers Rapid, large-scale screening to characterize the different subpopulations of multipotent cells that can be derived from fat tissue is an effective strategy to identify and select for specific cell types that would be advantageous for particular...
| | By Blue Horizon International Dr. Mehling, a board-certified orthopedic surgeon and CMO of Blue Horizon International (BHI), will present “Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation" at...
| By Visiongain Who are the leading developers and producers of stem cells in 2015, and what are their outlooks? Visiongain’s new study explains A new report by visiongain predicts the world stem cell technology market will generate $13.8bn in 2019, with rapid sales...
| By Visiongain LONDON, UK, 3rd of February 2015: A new report by visiongain calculates that the global translational regenerative medicine market will reach $4.8bn in 2015 with revenues showing growth to 2025.
| By Visiongain Visiongain’s new report predicts the world stem cell technologies market will reach $7.2bn in 2014. The overall industry will earn $12bn in 2018, achieving high revenue growth from 2015 to 2025.
| By Regenerative Technology Alliance RTA, a global provider of standards & certification for the emerging fields of regenerative medicine & science announces the strategic alliance with HHS Registered Institutional Review Board (IRB).
| By Medical Tourism Association® Panel Discussion Examines "Innovations in Stem Cell Treatments and Regenerative Medicine," Sept. 20, 2014, in Washington, D.C.
| By Blue Horizon Charitable Foundation Karina C. Tyler is a busy executive assistant who lives and works in New York City. Originally from Brazil, she juggles her limited time between her career, her family, and her passion for sports and travel.
| By Mary Ann Liebert, Inc., publishers Contact: Vicki Cohn, (914) 740-2156, vcohn@liebertpub.com Inner Ear Stem Cells Hold Promise for Restoring Hearing New Rochelle, NY—Spiral ganglion cells are essential for hearing and their irreversible degeneration in the inner ear is common in most...
| By Carmell Therapeutics Corp. Carmell Therapeutics, a company that is developing novel products manufactured from blood plasma, which naturally accelerate the healing of injured tissues, is pleased to announce that it has been awarded a Phase I Small Business Innovation Research...
| | By Xcelthera Inc Xcelthera Inc Secures First U.S. Patent for Large-Scale Production of High Quality Human Embryonic Stem Cells and their Neuronal and Heart Muscle Cell Therapy Products
| By Dr. Dennis Lox Autologous Stem Cells from Teen Soccer Player's Body Were The Key to Healing Her Avascular Necrosis, Saving Her Ankle from Fusion, Which Would Have Ended Her Ability to Play Soccer
|
Page updated every 10 minutes
| |
